Connection
Robert MacLaren to Cost-Benefit Analysis
This is a "connection" page, showing publications Robert MacLaren has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.138 |
|
|
|
-
MacLaren R, Campbell J. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*. Crit Care Med. 2014 Apr; 42(4):809-15.
Score: 0.090
-
MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health. 2005 Mar-Apr; 8(2):105-16.
Score: 0.048